Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Light Chain Bioscience.

    Client Virtual Booth

    LIGHT CHAIN BIOSCIENCE

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Light Chain Bioscience
    Switzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    NovImmune SA Chemin des Aulx 14 CH-1228 Plan-Les-Ouates
    Telephone
    Telephone
    +41 22 552 72 00
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.lightchainbio.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Edesa Biotech and Light Chain Bioscience Sign License Agreement to Develop Treatments for COVID-19 Pneumonia and Other Disorders

    Details:

    The companies singed this exclusive worldwide license to develop and commercialize two Phase 2-ready biologic drug candidates for all therapeutic, prophylactic and diagnostic applications.


    Lead Product(s): NI-0101

    Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

    Highest Development Status: UndisclosedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Edesa Biotech

    Deal Size: $372.0 million Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement April 20, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Novimmune unit nabs Takeda milestone payment for hemophilia work

    Details:

    The milestone was achieved upon the successful completion of the discovery phase and designation by Takeda of undisclosed bispecific antibodies with approval to advance to IND-enabling studies.


    Lead Product(s): Bispecific antibodies

    Therapeutic Area: Genetic Disease Product Name: Undisclosed

    Highest Development Status: DiscoveryProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Takeda Pharmaceutical

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration February 13, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search